Indications and uses
For treatment of airborne allergies, contact allergies and neurodermatitis.
For treatment of airborne allergies, contact allergies and neurodermatitis.
Dissolve 1 tablet in mouth or under tongue away from meals, 3 times daily, or as directed by a licensed practitioner. Consult a practitioner about children's dosages.
Store at room temperature. To report serious adverse events, contact BioResource, 321B Blodgett St., Cotati, CA 94931. Rev. 02/11
Drug Facts
Penicillium frequentans 4X
Allergies
For treatment of airborne allergies, contact allergies and neurodermatitis.
Stop use and ask a doctor if symptoms persist.
As with any drug, if pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children.
Dissolve 1 tablet in mouth or under tongue away from meals, 3 times daily, or as directed by a licensed practitioner. Consult a practitioner about children's dosages.
Store at room temperature. To report serious adverse events, contact BioResource, 321B Blodgett St., Cotati, CA 94931. Rev. 02/11
DISTRIBUTED BY:
BioResource Inc., Cotati, CA 94931
MANUFACTURED IN GERMANY FOR:
Syntrion® GmbH, 75365 Calw, Germany
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 10424-156-40 | 2019-10-29 | C162847 | 48780-1 | 960f7f55-c0a4-8e05-e053-dbdaa90a074a | SyAllgen |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 10424-156-40 | SyAllgen | 90 in 1 BOTTLE | TABLET | 90 | 1 | |
| 10424-156-40 | SyAllgen | 1 in 1 CARTON | TABLET | 1 | 1 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Penicillium Glabrum | ACTIVE INGREDIENT | 2IN23YUE0I | 1 | |
| Penicillium Glabrum | ACTIVE MOIETY | 2IN23YUE0I | 1 | |
| lactose | INACTIVE INGREDIENT | J2B2A4N98G | 1 | |
| magnesium stearate | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| powdered cellulose | INACTIVE INGREDIENT | SMD1X3XO9M | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 10424-156 | 10424-156-40 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Penicillium Glabrum | 2IN23YUE0I | ACTIB |
| powdered cellulose | SMD1X3XO9M | IACT |
| lactose | J2B2A4N98G | IACT |
| magnesium stearate | 70097M6I30 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | PASTE, DENTIFRICE / DENTAL | NA | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, DELAYED RELEASE / ORAL | 144 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | TABLET, COATED / ORAL | 40.2 mg | ||
| lactose | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | TABLET / BUCCAL | 4.5 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 47 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / SUBCUTANEOUS | 0.5 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FOR SUSPENSION / ORAL | 131 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | LIQUID / ORAL | NA | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, DELAYED RELEASE / ORAL | 1060 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION / ORAL | 64 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | GRANULE, FOR SUSPENSION / ORAL | 14 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / INTRAVITREAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | TABLET / ORAL | 1582 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | PELLET / ORAL | 24 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | SYSTEM / INTRAVITREAL | 0.02 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | DROPS / ORAL | NA | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | DISC / TOPICAL | NA | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | CREAM / TOPICAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | POWDER, FOR SUSPENSION / ORAL | 1600 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | RING / VAGINAL | 2 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TROCHE / ORAL | 315 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, SUGAR COATED / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | TABLET, CHEWABLE / ORAL | NA | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | SUSPENSION / ORAL | 1600 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, EXTENDED RELEASE / ORAL | 173 mg | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | DROPS / ORAL | NA | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / ORAL | 420 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION, EXTENDED RELEASE / ORAL | 71 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | INHALANT / ORAL | 0.08 mg | ||
| powdered cellulose | POWDERED CELLULOSE | SMD1X3XO9M | TABLET, DELAYED RELEASE / ORAL | 16 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| e94b8d4b-bc32-4b56-a3b7-af768233b5d6 | ae79eb99-af23-4dfd-b45a-0ba023573e1c | 2011-07-07 | Warnings | e94b8d4b-bc32-4b56-a3b7-af768233b5d6 ae79eb99-af23-4dfd-b45a-0ba023573e1c |
Adverse event summaries are temporarily unavailable. Other product information remains available.